Background: Acute coronary syndrome (ACS) is a leading cause of morbidity and mortality worldwide. Objectives: To describe patient profile, treatment patterns, and disease burden for patients with ACS. Methods: A retrospective descriptive cohort study was conducted. Data were obtained from electronic medical records from seven Shanghai medical centers. Patients with at least one primary diagnosis of ACS from 2006 to 2012 were included. Patient ACS-related antithrombotic medication use, laboratory tests, key comorbidities, health care utilization, and direct medical costs were examined. Loglinear regression was conducted to explore factors associated with total direct medical costs. Results: The mean age for the 6601 patients included was 69.7 Ϯ 12.5 years, and most of the patients (73%) were men. Comorbidities included diabetes (18.2%), hypertension (21.2%), and hyperlipidemia (8.6%). Out of these, 6466 (98%) patients had been hospitalized for ACS with an average length of stay of 14.0 Ϯ 16.4 days per hospitalization. A total of 914 (13.8%) patients had emergency room visits. Of these, 93.5% received any antithrombotic therapy, including antiplatelet agents (92.7%) and anticoagulants (20.8%). ACSrelated direct medical costs (in yuan renminbi [¥]) were ¥18,421 Ϯ ¥24,741 per hospitalization, including costs for medications (¥6,776) and laboratory tests (¥1,355), and ¥2,894 Ϯ ¥7,060 per outpatient visit, including costs for medications (¥620) and laboratory tests (¥464). The higher direct medical cost was associated significantly (P o 0.05) with age, being male, antiplatelet and anticoagulant use, and several comorbid disease states (diabetes, hyperlipidemia, hypertension, and chronic kidney disease). Conclusions: Antithrombotic therapeutic treatments were commonly used among patients with ACS in Shanghai, China. Higher treatment costs for patients with ACS in Shanghai, China, involved their antithrombotic medication use and key comorbidities.
Introduction
Acute coronary syndrome (ACS) is a severe and life-threatening disease, which is a common manifestation of coronary artery disease (CAD) or coronary heart disease (CHD) that encompasses acute myocardial infarction (AMI) and unstable angina [1] [2] [3] [4] [5] . AMI includes both ST elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI) [2] [3] [4] [5] . Patients who are more likely to develop ACS often have certain risk factors, which include smoking, hypertension, diabetes, hypercholesterolemia, family history of CAD, overweight body habitus, or obesity [2, [6] [7] [8] [9] .
ACS is a major cause of mortality and morbidity in patients with cardiovascular disease (CVD), accounting for 50% of all CVD deaths [10] . In addition, ACS is associated with more than 2.5 million hospitalizations worldwide each year [11, 12] . According to the Heart Disease and Stroke Statistics 2014 Update from the American Heart Association, there were more than 625,000 hospital discharges of ACS, and this number increased to 1,141,000 when adding secondary hospital discharges of ACS in 2010 [13] .
According to the Report on Cardiovascular Diseases in China (2013), the prevalence of CVD is increasing and an estimated 290 million patients had a diagnosis of CVD in 2012 [14] . The prevalence of CHD was 4.6 per 1000 residents of all ages. There is a higher prevalence in urban population than in rural population [15] . At present, CVD is the major health concern in China and nearly 3.5 million patients die annually [14] . The increasing prevalence of CVD in the Chinese urban population may be partially driven by some major risk factors, such as the increasing prevalence of hypertension and overweight/obesity, the high proportion of smokers in this population, and the low proportion of adults indulging in sufficient physical activity [14] .
The economic burden associated with ACS medical treatment is substantial, even when indirect costs such as loss of productivity are not included. A recent Chinese report has shown that in 2012 the average medical spending for AMI per hospitalization was ¥16,892 (¥, yuan renminbi; US $1 ¼ ¥6.0) in China regardless of urban or rural area and the average days of hospitalization were 9.9 days [16] . Pharmacotherapy is important in AMI treatment, which accounted for 28.6% of the total medical spending [16] .
A universal health care insurance policy was implemented around 2010 in China. The exact nature of the coverage, which services are included and what proportion of the total cost is covered, is still evolving and varies across provinces and cities. There are four major health insurance schemes in China: 1) Employment-based medical insurance for urban workers: The scheme consists of a pooled fund for inpatient stays and individual medical savings accounts for outpatient visits. It is funded by payroll taxes from both employers and employees. 2) Urban-resident scheme targeted for those urban residents who are not covered by other schemes: It is funded by both urban residents and the local government. 3) Rural cooperative medical system for the rural population: It is funded by individual rural participants as well as by local and central governments. 4) Medical assistance program for low-income families: It is jointly funded by central and provincial governments.
Primary prevention for ACS focuses on smoking cessation, healthy eating, and exercise along with optimizing control of key risk factors such as hypertension, diabetes, and dyslipidemia [2, 3, 17] . Treatment for ACS varies depending on several factors, such as the type of patient presentation, the services or procedures the hospital can provide, and economic concern. Common treatments of ACS include pharmacotherapy (such as aspirin, thrombolytics, nitroglycerin, β-blockers, statins, angiotensinconverting enzyme inhibitors, and angiotensin receptor blockers) and coronary revascularization such as percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) [1, 2] .
The Antiplatelet Treatment Consensus from Relative Experts for ACS Patients Managed without Revascularization in 2009 was published by the Chinese Experts Group of ACS Patients Managed without Revascularization [18] . In this guideline, the following antiplatelet agents are recommended: aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors [18] . In 2012, the Chinese Society of Cardiology published an updated clinical guideline for patients with non-ST-segment elevation ACS [19] . In this clinical guideline, the following treatments are recommended: post-myocardial infarction therapy (including beta receptor blockers, nitrates, calcium channel blockers, angiotensin-converting enzyme, and nicorandil), antiplatelet therapy, anticoagulant therapy, statins, and revascularization (including PCI and CABG) [19] .
According to the China Patient-Centered Evaluative Assessment of Cardiac Events (China PEACE)-Retrospective Acute Myocardial Infarction Study [20] , the percentage of patients with STEMI who underwent revascularization procedures is increasing dramatically; for example, patients with STEMI who underwent PCI increased from 10.2% in 2001 to 27.6% in 2011. Pharmacotherapy still plays a very important role in the treatment of STEMI in China, possibly because patients who live in rural areas or small cities may have to receive pharmacotherapy only because the hospitals may not have the ability (such as lacking a skilled provider or facility) to perform the revascularization surgery. In 2011, the percentages of patients with STEMI who received aspirin, clopidogrel, and beta blockers within 24 hours were 91.2%, 80.7%, and 57.7%, respectively [20] .
Objective and Significance
Despite the high prevalence of CHD in China, there is very limited health technology assessment on ACS. The objective of this study was to describe the patient profile, treatment patterns, and disease burden for patients with ACS in China.
To our knowledge, no available study has been published to date on characterizing ACS in China from a health technology assessment perspective. Information on health care utilization, treatment patterns, and factors influencing the treatment cost of ACS can be disseminated to the medical community so that treatment or management of ACS can be enhanced in China.
Methods

Primary Data Source
Given the higher prevalence of ACS in the urban areas of China, we decided to use the Shanghai electronic medical record (EMR) databases that were developed by the Shanghai Food and Drug Administration Adverse Drug Reaction Center from multiple urban medical centers (hospitals) in Shanghai city. Shanghai is one of the most populated cities in China, with a population of 23.0 million (as per the 2010 China Population Census) [21] .
The Shanghai EMR data include both inpatient and outpatient records from seven medical centers. There are four major data files: 1) patients' demographic file: hospital ID, age, sex, date of birth, marriage status, and so on; 2) diagnosis file: date of hospital admission, date of discharge, diagnosis before discharge, and so on; 3) medication use file: drug name, dosage, date of medication use, cost of unit dose, and so on; and 4) the laboratory test and procedure file: procedure name, laboratory test name, laboratory test value, and so on. All data records are documented in Chinese.
Cohort Definition and Selection Procedures
A retrospective cohort design was selected for this study. Patients with at least one primary diagnosis of ACS, CAD, or CHD were selected on the basis of the discharge diagnosis in the medical record documented in outpatient and inpatient files between January 2006 and July 2012. The International Classification of Diseases, Ninth Revision and/or International Classification of Diseases, Tenth Revision codes were not available in the discharge diagnosis file. All diagnoses were documented in Chinese medical terms. According to medical practitioners in China, patients with ACS are commonly diagnosed using several possible terms related to CAD or CHD. We included all diagnosis terms in Chinese to identify and select the final study patients. We included both new and existing patients with ACS for the study cohort.
Study Medications, Treatment Cost, and Health Outcomes
Medication use pattern involves antiplatelet drug use, anticoagulant drug use, thrombolytic use, and some traditional Chinese medicine (TCM) or herbal medicines. The follow-up time was calculated from the first index date of ACS to the end of the study period or death date, whichever came first.
Health care resource utilization was measured, such as days of hospital stay, number of emergency room visits, total hospital cost, including that for laboratory test, Western medicine, TCM, herbal medicine, and hospital and physician fees. The direct medical cost was calculated as the sum of hospitalization cost,
Western medicine cost, TCM and herbal medicine cost, and other hospital fees that were retrieved from medical records. The direct medical cost includes all costs for both inpatient and outpatient treatments. The cost analysis was aimed at an individual patient's perspective. All costs were simply calculated in Chinese yuan renminbi (¥) currency without adjusting it for inflation.
Multiple covariates and comorbid conditions must be controlled when evaluating the association between treatment cost and different treatment regimens [4, 10, 11] . With the longitudinal EMR data, we were able to capture health outcomes and major medical comorbid conditions for the study patients. We reported key health outcomes such as death, ischemia, and bleeding. Death was identified from discharge status on the basis of the EMR data. Ischemia and bleeding were identified on the basis of the discharge diagnosis file. Key medical comorbid conditions included hypertension, stroke, diabetes mellitus, hyperlipidemia, obesity, depression, and chronic kidney disease.
Because of some outcome variables, we excluded death, ischemia, and bleeding as covariates in the regression model. Some potential covariates such as previous MI, previous CABG, and PCI were not included because we were unable to identify these variables appropriately in the EMR data.
Data Analysis
The study protocol was approved by the University of Cincinnati Institutional Review Board. The descriptive statistics (mean and SD for continuous variables and the number of patients and the percentage for categorical variables) were used to show the patients' demographic characteristics, treatment patterns of health utilization and medication use, health outcomes, and the total cost per hospitalization. A multiple linear regression analysis was conducted to examine the factors associated with log 10 scale of total cost per hospitalization. Because the data distribution of direct medical cost is skewed data, the data transformation of log total cost was conducted. All data analyses were conducted using SASs 9.1 version (SAS Institute Inc., Cary, NC). A significance level of 0.05 was used.
Results
A total of 6601 patients were included for this study. Patients with ACS were selected according to patients' diagnoses in different Chinese medical terms. Initially, there were 7887 ACS-related records from inpatient discharge files, 5213 ACS-related records from other inpatient files, and 2678 ACS-related records from outpatient files. Table 1 presents patients' demographic characteristics, comorbidities, and health outcomes. The mean age was 69.7 Ϯ 12.5 years. There were 4844 (73%) men and 663 deaths (10% mortality rate). As for key comorbidities, 18.2% of patients had diabetes, 21.2% had hypertension, and 8.6% had hyperlipidemia. Some variables such as depression, obesity, and tobacco smoking were very rarely found or not documented in the EMR database.
Health Utilization and Treatment Pattern
A total of 6466 (98%) patients had been hospitalized for ACS, with a mean of 14.0 Ϯ 16.4 days per hospitalization on the basis of the inpatient files (Table 2) . We analyzed each of their hospitalizations and found that the frequency of hospitalizations in this study cohort was 5825 (90.2%) patients with only one hospitalization record, 562 (8.7%) patients with two hospitalization records, 126 (2.0%) patients with three hospitalization records, and 70 (1%) patients with four or more hospitalization records.
Among these 6466 inpatients, 896 patients (13.8%) were admitted in the emergency department first. The ACS-related direct medical costs were ¥18,421 (about US $3,070) per hospitalization, with medication and laboratory tests accounting for ¥6,776 (about US $1,129) and ¥1,355 (about US $229), respectively. For outpatient visits, the cost per visit was ¥2894 (about US $482), with medication and laboratory tests accounting for ¥620 (about US $103) and ¥464 (about US $77), respectively. Table 3 presents the drug use pattern for patients with ACS. Of these, 93.5% received any antithrombotic therapy, including 92.7% with antiplatelet agents and 20.8% with anticoagulants. Aspirin, clopidogrel, cilostazol, enoxaparin, and dalteparin are commonly used antiplatelet and anticoagulant agents for patients with ACS in China. Names of many new drugs such as ticlopidine, ticagrelor, abciximab, danaparoid, dabigatran, reteplase, and tenecteplase were not found in patients' EMR data. Table 4 presents results from multiple linear regression analyses. The higher direct medical cost was associated significantly (P o 0.01) with older age, being male, marital status, and some key comorbidities such as diabetes, hyperlipidemia, hypertension, and chronic kidney disease. The regression model shows that patients receiving antithrombotic therapy (either antiplatelet or anticoagulant) had higher direct cost per hospitalization.
Hospital Cost and Associated Factors
Discussion
To our knowledge, this study is the first attempt to use this kind of Chinese EMR data for health technology assessment. Antithrombotic therapeutic treatments were commonly used among patients with ACS in Shanghai, China. There were 663 (10%) patients who died during discharge in our study cohort, which is higher than the mortality rate (3.3%) reported in the EPICOR (long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome patients) study in Asia. Although the EPICOR cohort patients were from eight countries/ regions, 63.6% patients were from China. It is that the present study patients (mean age ¼ 69.7 years) were older than the EPICOR Asia cohort patients (mean age ¼ 60 years). The followup period was also different between the two studies. The present study patients showed that 21% had hypertension and 2% had a stroke, which is similar to the rate reported in the EPICOR Asia study. There was a higher rate of bleeding (2.8%) within 1-year follow-up in the EPICOR Asia patients [22] compared with the rate of bleeding (0.5%) in our study patients. It is possible that our study data did not capture the patients' medical conditions after discharge from the hospital. We are unclear as to why the rate of surgical procedure (0.4%) for study patients was relatively low.
The present study indicates that per-hospitalization cost for patients with ACS was about US $3,000 (¥18,421). This posed a significant disease burden on the health care system and patients because the cost was equivalent to the gross domestic product (GDP) per capita in China during the study period. Major hospital cost components were for Western medicine and hospital/physician fees. The higher treatment cost for patients with ACS involves antithrombotic medication use and key medical comorbidities such as diabetes, hypertension, chronic kidney disease, and hyperlipidemia. In our study, 93.5% of patients received any of the antithrombotic medications. Both antiplatelet and anticoagulant drugs are essential for ACS treatment although costeffectiveness analysis is beyond the scope of this present study. This cost study indicates that health insurance coverage is critical for patients with ACS.
In 2012, China became the second largest economy in the world and had an annual GDP of US $9.24 trillion [23] . Meanwhile, the total expenditure on health as a percentage of GDP also kept increasing, from 4.5% in 2000 to 5.4% in 2012 [24] . In 2008, more than 318 million urban residents received health insurance coverage, including public health insurance, employment-based health insurance, and urban resident health insurance [25] . As a milestone, the Chinese government had been investing heavily in health care reform, with an additional ¥850 billion (equivalent to US $140 billion) from 2009 to 2011, to establish a universal health insurance system that provided "safe, effective, convenient, and affordable basic health services" [26] .
In addition, China spent ¥946.8 billion on medicines in 2011, accounting for 37.6% of total health expenditure [27] . According to IMS Health, China, as one of the largest and fastest growing market, is expected to become the second largest pharmaceutical market in the world with total sales of more than US $165 billion by 2016 [28] . Another prognosis report of IMS Health also pointed out that the pharmaceutical market is expected to grow at an annual rate ranging between 14% and 17% from 2013 to 2017 [29] .
This study involved several limitations. The study population was based on one large urban city; thus, results may not be generalizable to other Chinese populations. According to our ACS, acute coronary syndrome. * Patients might receive multiple medications during the study period. It is not mutually exclusive. † Both brand name and generic name were used to search for patient medications. There was no use for several medications listed here, such as prasugrel (Effient), antithrombin (Atryn), and tenecteplase (TNKase) because these had not been approved by the China Food and Drug Administration during the study period.
personal communication with health care practitioners in Shanghai, more than 90% of patients with ACS are sent to big hospitals (tier 3 and tier 2 hospitals) directly when they are suspected as experiencing ACS by an electrocardiogram in the ambulance. Tier 2 hospitals must have at least 100 inpatient beds providing acute medical care and preventative care services to populations of at least 100,000. Tier 3 hospitals are major tertiary referral centers in major cities (such as Shanghai) or provincial capitals. Other patients who are identified as experiencing ACS in outpatient settings are also sent to big hospitals. The EMR data were collected mainly from tier 2 medical centers, and these data may not have captured all critical treatment and surgical procedures. From the EMR database, data for most of the patients diagnosed with ACS were retrieved from inpatient files. During the study period, we were unable to capture their complete data of follow-up outpatient care. In addition, the researcher's ability to identify cases with ACS is limited to those that can be picked up in the available hospital EMRs.
Conclusions
Antithrombotic therapeutic treatments were commonly used among patients with ACS in Shanghai, China. The higher treatment cost for patients with ACS involves their antithrombotic medication use and key comorbidities. Future ACS health technology assessment should focus on critical health outcomes such as mortality and recurrent ischemia in an attempt to identify their association with medication use and key risk factors because ACS poses a significant disease burden on the health care system and patients. V A L U E I N H E A L T H R E G I O N A L I S S U E S 9 C ( 2 0 1 6 ) 9 3 -9 8
